genolimzumab + bozitinib

Genolimzumab + bozitinib is a **combination of two pharmacological agents**. - **Genolimzumab** is a humanized IgG4 monoclonal antibody directed against the **programmed cell death protein 1 (PD-1) receptor** on immune cells. By blocking PD-1, it functions as an **immune checkpoint inhibitor** to potentiate antitumor immunity and is being developed primarily for use in **cancer immunotherapy**[6]. - **Bozitinib** is a small molecule kinase inhibitor (based on naming conventions, presumed mechanism, but there is currently no public domain clinical or preclinical data specifically about bozitinib; see comments for further detail). The combination is investigational with primary development focus in oncology.